INTRODUCTION {#sec1-1}
============

Testicular cancer is a rare disease. A total of 78 cases have been diagnosed in 2010, with an age standardized rate of 0.8 cases/100,000 representing 1.7% of all diagnosed cancer in Saudi males ([www.scr.org.sa](http://www.scr.org.sa)). Owing to the rarity of the disease and the multidisciplinary approach in managing testis cancer, the group recommended that all testicular cancer cases should be managed in tertiary care centers.

StagingThe American Joint Committee on Cancer tumor-node-metastasis staging for testis cancer (7^th^ edition 2010) was used.\[[@ref1]\]Evaluation of testicular tumors2.1.Ultrasound of the scrotum is recommended to diagnose the tumor2.2.Serum tumor markers includes alpha fetoprotein (AFP), beta human chorionic gonadotropin (beta-hCG), and lactate dehydrogenase should prior to orchiectomy2.3.Computed tomography (CT) chest, abdomen, and pelvis should performed for confirmed testicular cancer.Risk stratificationThe International Germ Cell Cancer Collaborative Group risk classification.Treatment of testicular germ cell cancerGeneral considerations:Patients at all stages should undergo urgent inguinal orchiectomy unless the clinical situation requires immediate chemotherapy in patients with a testicular mass and clear germ cell malignancy based on elevated tumor markersTrans-scrotal biopsy or orchiectomy for any intra-testicular lesion is absolutely contra-indicatedAll patients who will undergo treatment with chemotherapy, retroperitoneal lymph node dissection (RPLND), or radiotherapy should be offered sperm banking. To maintain treatment intensity, chemotherapy cycles should be repeated every 3 weeks, independent of leukocyte countTumor markers are to be determined immediately before the start of each new chemotherapy cycle.The treatment will depend on the histological subtype as follow:4.1.SeminomaFurther treatment will depend on the stage:4.1.1.Stage I4.1.1.1Surveillance: Is considered the preferred strategy, except in patients with expected poor compliance or with primary tumor size ≥4 cm and ≥pT2 (evidence level \[EL-1\])\[[@ref2]\]4.1.1.2Chemotherapy: Single agent carboplatin: 1--2 doses at area under the curve 7 (EL-1)\[[@ref3]\]4.1.1.3Radiotherapy: Infradiaphragmatic para-aortic strip only and in patient with prior scrotal surgery, ipsilateral iliac nodes should be included (EL-1).\[[@ref4][@ref5]\]4.1.2.Stage IS4.1.2.1Infradiaphragmatic radiotherapy to para-aortic strip only and in patient with prior scrotal surgery, ipsilateral iliac nodes should be included (EL-3).\[[@ref6]\]4.1.3.Stage IIA and IIB, all of the following options are acceptable4.1.3.1Radiotherapy to infradiaphragmatic para-aortic and ipsilateral Iliac nodes, preferred for stage IIA and for stage IIB who are not fit for chemotherapy (EL-2)\[[@ref7]\]4.1.3.2Three cycles of bleomycin, etoposide, and cisplatin (BEP) chemotherapy or four cycles of etoposide and cisplatin (EP), if there are concerns about bleomycin toxicity as in patients with reduction in lung capacity, emphysema, heavy smoking (including former smokers) (EL-2).4.1.4.Stage IIC and III: Treatment will depend on the risk classification4.1.4.1Good risk: Three cycles of BEP chemotherapy or four cycles of EP, if there are concerns about bleomycin lung toxicity (EL-1)\[[@ref8]\]4.1.4.2Intermediate risk: Chemotherapy with four cycles of BEP or four cycles of VIP chemotherapy (etoposide, ifosfamide, and cisplatin) (EL-1).\[[@ref9]\]4.1.5.Management of postchemotherapy residual nodes/masses seen on computed tomography scan: This depend on the size and the level of tumor markers (hCG):4.1.5.1If size \<3 cm and normal markers: Surveillance4.1.5.2If more than 3 cm and normal markers: Do positron emission tomography:\[[@ref10]\]4.1.5.3If negative: Surveillance (EL-2).4.1.5.4If positive consider one of the following options:4.1.5.4.1.Surgical resection4.1.5.4.2.Second-line chemotherapy if positive for residual disease (see item 4.2.1.6.3.2)4.1.5.4.3.Radiotherapy4.1.5.5If the residual mass is enlarging or markers increasing: Second-line chemotherapy (EL-2) - (see item 4.2.1.6.3.2).4.1.6.Management of patients failing 1^st^ line chemotherapy: Patients will receive second-line chemotherapy; options are:4.1.6.1Four cycles of vinblastine, ifosfamide, and cisplatin (VeIP) regimen\[[@ref11]\] (EL-2) or4.1.6.2Four cycles of paclitaxel, ifosfamide, and cisplatin (TIP) regimen (EL-2).\[[@ref12]\]4.1.7.Management of patients failing second-line chemotherapy: Patients will be treated with monotherapy or combination of paclitaxel and gemcitabine (for those who did not receive paclitaxel before), gemcitabine and oxaliplatin, or oral etoposide.\[[@ref13]\]4.2.NonseminomaTreatment will depend on the stage as follow:4.2.1.Stage ITreatment will depend on the presence of any the following risk factors: Lymphovascular invasion, presence of embryonal histology (50% or more), absence of yolk sac histology, and tumor stage \> T1.\[[@ref14][@ref15]\]4.2.1.1Stage I with no risk factors, options are:4.2.1.1.1.Surveillance: Should be reserved in compliant patients (EL-2).\[[@ref16][@ref17]\]4.2.1.1.2.Two cycles of BEP regimen (EL-1),\[[@ref16][@ref17][@ref18]\] also one cycle of BEP chemotherapy can be considered in such cases\[[@ref18]\]4.2.1.1.3.Open nerve sparing RPLND to be done only in high volume tertiary care centers (EL-2),\[[@ref18]\] further therapy will depend on the pathological result as follow:4.2.1.1.3.1.pN0: Surveillance4.2.1.1.3.2.pN1: Surveillance in compliant patients or two cycles of chemotherapy with BEP in noncompliant patients (EL-3)4.2.1.1.3.3.pN2-3: Three cycles of chemotherapy with BEP regimen (EL-3).4.2.1.2Stage I with any risk factor of above, options are:4.2.1.2.1.Two cycles of adjuvant chemotherapy with BEPm regimen\[[@ref16]\]4.2.1.2.2.Open nerve sparing RPLND: To be done only in case of contraindication for chemotherapy and in high volume tertiary care centers (EL-2):\[[@ref19]\] Further therapy will depend on the pathological stage as in item 4.2.1.1.3.1-3.4.2.1.3Stage IS:Patient should receive three cycles of systemic chemotherapy with the BEP regimen (EL-3).4.2.1.4Stage IIA and IIB: Options of therapy will depend if markers (AFP and hCG) are normal or elevated:4.2.1.4.1.Normal markers, options are:4.2.1.4.1.1.Primary chemotherapy with three cycles of BEP.\[[@ref8]\]4.2.1.4.1.2.Open nerve sparing RPLND,\[[@ref20][@ref21]\] only if the nodal metastases is in the primary landing zone and in selected patients, it should be done only in high volume center by experienced uro-oncologist. Further therapy will depend on the pathological stage as in item 4.2.1.1.3.1-3.4.2.1.4.2.Elevated markers: Systemic chemotherapy depending on the international risk classification group:4.2.1.4.2.1.Low risk: Three cycles of BEP chemotherapy.\[[@ref7][@ref8]\]4.2.1.4.2.2.Intermediate and high risk: Four cycles of BEP chemotherapy.\[[@ref9]\]4.2.1.5Stage IIC and III: Treatment will be with chemotherapy depending on the international risk classification4.2.1.5.1.Low risk: Three cycles of BEP chemotherapy.\[[@ref7][@ref8]\]4.2.1.5.2.Intermediate and high risk: Four cycles of BEP chemotherapy.\[[@ref9]\]4.2.1.6Management of postchemotherapy: Tumor markers and imaging with CT scan should be done 4--8 weeks after the last cycle of chemotherapy.4.2.1.6.1.No residual disease and normal markers: Surveillance is recommended.\[[@ref22]\]4.2.1.6.2.No residual disease and elevated markers: Second-line chemotherapy. See item 4.2.1.6.3.24.2.1.6.3.Residual disease by CT scan (\>1 cm): This depends on the level of serum markers:4.2.1.6.3.1.Normal markers: RPLND and resection of all residual disease, if technically feasible:\[[@ref23][@ref24]\] Further therapy will depend on pathology result:4.2.1.6.3.1.1Mature teratoma, necrosis, or fibrosis: No further therapy4.2.1.6.3.1.2Residual germ cell tumor: Two cycles of chemo therapy\[[@ref25]\] with E P, VIP or TIP (see below) (EL-2).4.2.1.6.3.2.Elevated markers: Second-line chemotherapy options include4.2.1.6.3.2.1Four cycles of VeIP regimen.\[[@ref11]\]4.2.1.6.3.2.2Four cycles of TIP regimen.\[[@ref12]\]4.2.1.6.3.2.3High-dose chemotherapy with autologous stem-cell transplant.\[[@ref26]\]Salvage treatment for seminoma and nonseminoma

5.1.Conclusive recommendations cannot be made at present5.2.Prognosis is variable with 2 years survival rate ranging between 75% and 6% based on prognostic score5.3.Options includes TIP × 4 or VeIP × 4 or high-dose chemotherapy with TI-CE mainly for patients at second-line setting5.4.Carboplatin based high-dose chemotherapy as third line or later is an option, despite absence of randomized trials in this area5.5.Desperation surgery should be part of the strategy whenever possible, particularly in patients with localized disease and with poor response to chemotherapy.\[[@ref27]\]
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